Recruiting
Gastrooesophageal cancer+2
RecruitingStudy of Simvastatin with Nivolumab and Oxaliplatin for Patients with Advanced Stomach or Esophageal Cancer with ARID1A Mutation
Registered drugNo placebo
Study of Simvastatin with Nivolumab and Oxaliplatin for Patients with Advanced Stomach or Esophageal Cancer with ARID1A Mutation
Registered drugNo placebo
- Disease:Gastrooesophageal cancerHuman epidermal growth factor receptor negative+1
- Substances:CapecitabineFluorouracil+3
Countries:
Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Capecitabine
- Sponsor:IRCCS Istituto Nazionale Tumori Fondazione Pascale
